Partnerships might be imminent according to The Prof.Over the...

Partnerships might be imminent according to The Prof.

Over the years Mesoblast has secured a number of partnership deals. It's most important was with drug maker Cephelon, with whom it inked a $US2 billion deal in 2010...
Itescu says Mesoblast had a "great" partnership with Cephelon and Teva exited because it was a generic drug focused company.

He adds right now he is "engaged in a number of significant discussions with pharmaceutical companies and some of the assets we are building are very likely to be part of (those talks)."

Mesoblast also has a partnership with Swiss-based Lonza Group. It also reached a deal with China's Tasly Pharmaceutical Investments in 2018, which resulted in the group taking a 2.7 per cent stake for developing and marketing Mesoblast's drug candidates for heart failure in China. More recently Mesoblast reached a similar type deal with Germany's Grünenthal, for its chronic back pain candidate for Europe and Latin America.

Glta